Diagnostic and statistical manual of mental disorders American Psychiatric Association, 2000. ,
F o l s t e i nM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, pp.939-983, 1984. ,
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories, Neurobiology of Aging, vol.18, issue.4, pp.351-358, 1997. ,
DOI : 10.1016/S0197-4580(97)00056-0
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, issue.6, pp.1158-65, 1999. ,
DOI : 10.1212/WNL.52.6.1158
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007. ,
DOI : 10.1016/S1474-4422(07)70178-3
The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011. ,
DOI : 10.1016/j.jalz.2011.03.008
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Annals of Neurology, vol.107, issue.suppl 1, pp.306-325, 2004. ,
DOI : 10.1002/ana.20009
PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiology of Aging, vol.29, issue.10, pp.1456-65, 2008. ,
DOI : 10.1016/j.neurobiolaging.2007.03.029
11C-PiB PET assessment of change in fibrillar amyloid-?? load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, The Lancet Neurology, vol.9, issue.4, pp.363-72, 2010. ,
DOI : 10.1016/S1474-4422(10)70043-0
[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease, Neurology, vol.67, issue.3, pp.446-52, 2006. ,
DOI : 10.1212/01.wnl.0000228230.26044.a4
Relationships between biomarkers in aging and dementia, Neurology, vol.73, issue.15, pp.1193-1202, 2009. ,
DOI : 10.1212/WNL.0b013e3181bc010c
2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients, Journal of Nuclear Medicine, vol.48, issue.4, pp.553-61, 2007. ,
DOI : 10.2967/jnumed.106.037556
Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease, Journal of the Neurological Sciences, vol.285, issue.1-2, pp.100-108, 2009. ,
DOI : 10.1016/j.jns.2009.06.005
Voxel-Based Analysis of Amyloid Positron Emission Tomography Probe [11C]BF-227 Uptake in Mild Cognitive Impairment and Alzheimer???s Disease, Dementia and Geriatric Cognitive Disorders, vol.30, issue.2, pp.101-112, 2010. ,
DOI : 10.1159/000318754
PET of Brain Amyloid and Tau in Mild Cognitive Impairment, New England Journal of Medicine, vol.355, issue.25, pp.2652-63, 2006. ,
DOI : 10.1056/NEJMoa054625
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer???s disease pathologies, Journal of Neurochemistry, vol.57, issue.2, pp.623-653, 2009. ,
DOI : 10.1111/j.1471-4159.2009.05996.x
F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial, Annals of Neurology, vol.9, issue.3, pp.319-348, 2010. ,
DOI : 10.1002/ana.22068
Imaging of amyloid ?? in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, The Lancet Neurology, vol.7, issue.2, pp.129-164, 2008. ,
DOI : 10.1016/S1474-4422(08)70001-2
Cerebral amyloid-?? PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study, The Lancet Neurology, vol.10, issue.5, pp.424-459, 2011. ,
DOI : 10.1016/S1474-4422(11)70077-1
The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience, Q J Nucl Med Mol Imaging, vol.53, pp.387-93, 2009. ,
Preclinical Properties of 18F-AV-45: A PET Agent for A?? Plaques in the Brain, Journal of Nuclear Medicine, vol.50, issue.11, pp.1887-94, 2009. ,
DOI : 10.2967/jnumed.109.065284
Use of Florbetapir-PET for Imaging ??-Amyloid Pathology, JAMA, vol.305, issue.3, pp.275-83, 2011. ,
DOI : 10.1001/jama.2010.2008
Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent ??? a pilot study, Nuclear Medicine and Biology, vol.37, issue.4, pp.497-508, 2010. ,
DOI : 10.1016/j.nucmedbio.2010.02.003
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18), Journal of Nuclear Medicine, vol.51, issue.6, pp.913-933, 2010. ,
DOI : 10.2967/jnumed.109.069088
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease, Archives of Neurology, vol.68, issue.11, pp.1404-1415, 2011. ,
DOI : 10.1001/archneurol.2011.150
Mild Cognitive Impairment, Archives of Neurology, vol.56, issue.3, pp.303-311, 1999. ,
DOI : 10.1001/archneur.56.3.303
URL : https://hal.archives-ouvertes.fr/inserm-00112038
Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study, Neurology, vol.69, issue.19, pp.1859-67, 2007. ,
DOI : 10.1212/01.wnl.0000279336.36610.f7
URL : https://hal.archives-ouvertes.fr/inserm-00169640
Mental status examination for organic mental syndrome in the elderly patient, Geriatric psychiatry, pp.77-121, 1976. ,
Screening for dementia by memory testing, Neurology, vol.38, issue.6, pp.900-903, 1988. ,
DOI : 10.1212/WNL.38.6.900
Picture Confrontation Oral Naming: Performance Differences between Aphasics and Normals, Brain and Language, vol.53, issue.1, pp.105-125, 1996. ,
DOI : 10.1006/brln.1996.0039
Diagnostic validity of a standardized neuropsychological battery derived from Luria's Neuropsychological Tests., Journal of Consulting and Clinical Psychology, vol.46, issue.6, pp.1258-65, 1978. ,
DOI : 10.1037/0022-006X.46.6.1258
Validation d???une batterie br??ve d?????valuation des praxies gestuelles pour consultation M??moire. ??valuation chez 419 t??moins, 127 patients atteints de troubles cognitifs l??gers et 320 patients atteints d???une d??mence, Revue Neurologique, vol.165, issue.6-7, pp.560-567, 2009. ,
DOI : 10.1016/j.neurol.2008.11.016
Manuel: test de copie et de reproduction de mémoire de figures géométriques complexes. Paris: Centre de Psychologie Appliquée, 1959. ,
Scoring the Stroop test, Acta Psychologica, vol.24, pp.398-408, 1965. ,
DOI : 10.1016/0001-6918(65)90024-7
Wechsler Memory Scale Revised manual. San Antonio: The Psychological Corporation, 1987. ,
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE, Perceptual and Motor Skills, vol.19, issue.3, pp.271-277, 1958. ,
DOI : 10.2466/pms.1958.8.3.271
Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease, Nuclear Medicine and Biology, vol.37, issue.8, pp.917-942, 2010. ,
DOI : 10.1016/j.nucmedbio.2010.05.001
R: A language and environment for statistical computing. R Foundation for Statistical Computing ISBN 3-900051-07-0. URL http Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, Brain, vol.131, pp.1630-1675, 2008. ,
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B, Journal of Neuroscience Methods, vol.172, issue.2, pp.277-82, 2008. ,
DOI : 10.1016/j.jneumeth.2008.05.005
Imaging ??-amyloid burden in aging and dementia, Neurology, vol.68, issue.20, pp.1718-1743, 2007. ,
DOI : 10.1212/01.wnl.0000261919.22630.ea
Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias, Journal of Nuclear Medicine, vol.52, issue.8, pp.1210-1217, 2011. ,
DOI : 10.2967/jnumed.111.089730
Striatal ??-amyloid in dementia with Lewy bodies but not Parkinson???s disease, Journal of Neural Transmission, vol.65, issue.12, pp.713-722, 2011. ,
DOI : 10.1007/s00702-011-0641-6
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease, Brain, vol.131, issue.7, pp.1845-53, 2008. ,
DOI : 10.1093/brain/awn107
Amyloid PET in mild cognitive impairment and Alzheimer???s disease with BF-227: comparison to FDG???PET, Journal of Neurology, vol.355, issue.5, pp.721-728, 2010. ,
DOI : 10.1007/s00415-009-5396-8
Fibrillar amyloid-?? burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.106, issue.16, pp.6820-6825, 2009. ,
DOI : 10.1073/pnas.0900345106
Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ??4 Genotype in Alzheimer's Disease, Biological Psychiatry, vol.68, issue.10, pp.879-84, 2010. ,
DOI : 10.1016/j.biopsych.2010.05.013